Supplemental Evidence and Data Request on Fiber Intake and Laxation Outcomes, 21521-21523 [2024-06595]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 61 / Thursday, March 28, 2024 / Notices
Statutory authority for the collection
of information associated with the
CBPA is contained in Sections 154(i),
307, 308, 309, and 319 of the
Communications Act of 1934, as
amended, the Community Broadcasters
Protection Act of 1999, and the Middle
Class Tax Relief and Job Creation Act of
2012.
Total Annual Burden: 460 hours.
Annual Cost Burden: $41,725.
Needs and Uses: The FCC Form 2100,
Schedule F is used by Low Power TV
(LPTV) stations that seek to convert to
Class A status; existing Class A stations
seeking a license to cover their
authorized construction permit
facilities; and Class A stations entering
into a channel sharing agreement. The
FCC Form 2100, Schedule F requires a
series of certifications by the Class A
applicant as prescribed by the
Community Broadcasters Protection Act
of 1999 (CBPA). Licensees will be
required to provide weekly
announcements to their listeners: (1)
informing them that the applicant has
applied for a Class A license and (2)
announcing the public’s opportunity to
comment on the application prior to
Commission action.
On December 11, 2023, the
Commission adopted a Report and
Order, FCC 23–112, to implement the
Low Power Protection Act (LPPA or
Act), which was enacted on January 5,
2023. The LPPA provides certain low
power television (LPTV) stations with a
limited window of opportunity to apply
for primary spectrum use status as Class
A television stations. The Report and
Order establishes the period during
which eligible stations may file
applications for Class A status,
eligibility and interference
requirements, and the process for
submitting applications. The Report and
Order provides that applications to
convert to Class A status under the Low
Power Protection Act must be filed
using FCC Form 2100, Schedule F. The
application form requires certifications
by the applicant as prescribed by the
LPPA. This submission is being made to
OMB for approval of the modified FCC
Form 2100, Schedule F. In addition,
LPTV stations that file an application to
convert to Class A status must provide
local public notice of the filing of the
application pursuant to 47 CFR
73.3580(c). Specifically, the station
must both broadcast on-air
announcements and give online notice.
This submission also reflects the burden
associated with that information
collection and is also being made to
request Office of Management and
Budget (OMB) approval of that
collection.
VerDate Sep<11>2014
20:27 Mar 27, 2024
Jkt 262001
Federal Communications Commission.
Marlene Dortch,
Secretary, Office of the Secretary.
[FR Doc. 2024–06603 Filed 3–27–24; 8:45 am]
BILLING CODE 6712–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Supplemental Evidence and Data
Request on Fiber Intake and Laxation
Outcomes
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for supplemental
evidence and data submission.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) is seeking
scientific information submissions from
the public. Scientific information is
being solicited to inform our review on
Fiber Intake and Laxation Outcomes,
which is currently being conducted by
the AHRQ’s Evidence-based Practice
Centers (EPC) Program. Access to
published and unpublished pertinent
scientific information will improve the
quality of this review.
DATES: Submission Deadline on or
before April 29, 2024.
ADDRESSES:
Email submissions: epc@
ahrq.hhs.gov.
Print submissions:
Mailing Address: Center for Evidence
and Practice Improvement, Agency for
Healthcare Research and Quality,
ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A,
Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.):
Center for Evidence and Practice
Improvement, Agency for Healthcare
Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers
Lane, Mail Stop 06E77D, Rockville,
MD 20857
FOR FURTHER INFORMATION CONTACT:
Kelly Carper, Telephone: 301–427–1656
or Email: epc@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency for Healthcare Research and
Quality has commissioned the
Evidence-based Practice Centers (EPC)
Program to complete a review of the
evidence for Fiber Intake and Laxation
Outcomes. AHRQ is conducting this
review pursuant to Section 902 of the
Public Health Service Act, 42 U.S.C.
299a.
The EPC Program is dedicated to
identifying as many studies as possible
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
21521
that are relevant to the questions for
each of its reviews. In order to do so, we
are supplementing the usual manual
and electronic database searches of the
literature by requesting information
from the public (e.g., details of studies
conducted). We are looking for studies
that report on Fiber Intake and Laxation
Outcomes. The entire research protocol
is available online at: https://
effectivehealthcare.ahrq.gov/products/
fiber-intake/protocol.
This is to notify the public that the
EPC Program would find the following
information on Fiber Intake and
Laxation Outcomes helpful:
D A list of completed studies that
your organization has sponsored for this
topic. In the list, please indicate
whether results are available on
ClinicalTrials.gov along with the
ClinicalTrials.gov trial number.
D For completed studies that do not
have results on ClinicalTrials.gov, a
summary, including the following
elements, if relevant: study number,
study period, design, methodology,
indication and diagnosis, proper use
instructions, inclusion and exclusion
criteria, primary and secondary
outcomes, baseline characteristics,
number of patients screened/eligible/
enrolled/lost to follow-up/withdrawn/
analyzed, effectiveness/efficacy, and
safety results.
D A list of ongoing studies that your
organization has sponsored for this
topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the
trial is not registered, the protocol for
the study including, if relevant, a study
number, the study period, design,
methodology, indication and diagnosis,
proper use instructions, inclusion and
exclusion criteria, and primary and
secondary outcomes.
D Description of whether the above
studies constitute ALL Phase II and
above clinical trials sponsored by your
organization for this topic and an index
outlining the relevant information in
each submitted file.
Your contribution is very beneficial to
the Program. Materials submitted must
be publicly available or able to be made
public. Materials that are considered
confidential; marketing materials; study
types not included in the review; or
information on topics not included in
the review cannot be used by the EPC
Program. This is a voluntary request for
information, and all costs for complying
with this request must be borne by the
submitter.
The draft of this review will be posted
on AHRQ’s EPC Program website and
available for public comment for a
period of 4 weeks. If you would like to
be notified when the draft is posted,
E:\FR\FM\28MRN1.SGM
28MRN1
21522
Federal Register / Vol. 89, No. 61 / Thursday, March 28, 2024 / Notices
please sign up for the email list at:
https://effectivehealthcare.ahrq.gov/
email-updates.
The review will answer the following
questions. This information is provided
as background. AHRQ is not requesting
that the public provide answers to these
questions.
KQ 1a: How does the association vary
among people in different life stages?
Key Question (KQ)
KQ 1: What is the association between
fiber intake and laxation/gut motility in
apparently healthy individuals?
PICOTS (Populations, Interventions,
Comparators, Outcomes, Timing, and
Setting)
STUDY ELIGIBILITY CRITERIA BASED ON POPULATION, INTERVENTION, COMPARATOR, OUTCOME (PICO), AND OTHER
ELEMENTS
Element
Inclusion criteria
Exclusion criteria
Population ............................
• Individuals of any age, including pregnant or lactating
women.
• General population, including individuals with overweight/obese and those at elevated cardiometabolic
disease risk.
Æ Overweight/obese.
Æ Hyperglycemia and related conditions, including
type 2 diabetes.
Æ Dyslipidemia.
Æ Hypertension/high blood pressure.
Interventions .........................
• Fiber intake, including different types and sources of
fiber.
• Fiber naturally occurring in food, enriched in food, dietary supplements, and diets that can be defined on
the basis of fiber content.
Æ Must specify quantity of fiber intake.
Comparators ........................
•
•
•
•
•
•
•
•
•
•
• Those with diseases/health-related conditions or taking medications that could impact gut motility/laxation
(e.g., irritable bowel syndrome; chronic constipation;
lactose intolerance; use of medications that stimulate
laxation or cause constipation).
• Those with chronic constipation (100% of study population), including functional constipation.
• Study eligibility criteria includes ‘‘abnormal laxation’’
as defined by either a minimum or maximum number
of defecations per week (or equivalent).
• Those with other gastrointestinal-related conditions,
symptoms, diagnoses;
Æ Including diverticulosis.
• Those with diseases/health-related conditions or taking medications that could alter the gut microbiota
composition/diversity (e.g., antibiotics).
• Those with cancer, gastrointestinal disease, undernutrition, or who have had gut resection or bariatric
surgery.
• Those with acute illness or injury.
• Pre-term babies (gestational age <37 weeks), babies
with low birth weight (<2,500 g) or small for gestational age (per study criteria).
• Enteral/tube fed.
• Animal, in vitro, or other non-human studies.
• Diets (or other interventions or exposures) where the
fiber intake has not been quantified or explicitly specified.
• Combinations of fiber (from food or dietary supplements) and other entities with a purported effect on
motility, digestion, or microbiota (e.g., psyllium +
probiotic).
• Combinations of fiber supplements and other entities
(e.g., minerals, vitamins).
• Other entities with a purported effect on motility, digestion, or microbiota (e.g., probiotic).
• Alternative food group diets (e.g., red meat, fish, high
protein).
• Fiber + probiotic (etc.) vs. no intervention or placebo.
• Fiber + probiotic (etc.) vs. same probiotic (etc.).
• Fiber vs. probiotic (etc.).
• High-fiber diet vs. red meat diet (etc.).
Interventions vs. Comparators.
Outcomes .............................
ddrumheller on DSK120RN23PROD with NOTICES1
Subgroups of interest ...........
Design ..................................
VerDate Sep<11>2014
20:27 Mar 27, 2024
Different levels (dosages) of fiber.
No added fiber or placebo.
Different types or sources of fiber.
Different formulations of fiber.
Fiber (supplement) vs. no fiber (supplement).
Higher fiber (diet) vs. lower fiber (diet).
Fiber vs. alternative fiber.
Fiber vs. alternative fiber dose.
Fiber vs. alternative fiber formulation.
Laxation (i.e., gut motility).
Æ Fecal frequency (e.g., number of defecations per
week).
Æ Gastrointestinal transit time.
D Bristol stool scale (stool consistency).
D Dye, marker studies.
Æ Fecal output, weight/bulk (g/day).
Æ Ease of defecation (e.g., constipation).
• Specific life stages:
Æ Infants.
Æ Children and adolescents.
Æ Adults (19–64).
Æ Older adults (≥65).
Æ Pregnant or postpartum.
Æ Sex (male, female).
• Randomized controlled trials.
Æ Parallel or cross-over.
• N ≥10/group.
Jkt 262001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
• Other disease or health outcomes.
• Flatulence, eructation, bloating, etc.
None.
• Observational studies.
• All other study designs.
E:\FR\FM\28MRN1.SGM
28MRN1
Federal Register / Vol. 89, No. 61 / Thursday, March 28, 2024 / Notices
21523
STUDY ELIGIBILITY CRITERIA BASED ON POPULATION, INTERVENTION, COMPARATOR, OUTCOME (PICO), AND OTHER
ELEMENTS—Continued
Element
Inclusion criteria
Timing ..................................
• Minimum duration of intervention: 2 weeks.
• In cross-over studies, any change in outcome measure must exclude data from the first week after end
of any prior treatments. This may be accomplished
by a washout period of at least 1 week.
• General population.
• English language.
• Published in peer-reviewed journals.
Setting ..................................
Publication ............................
Dated: March 18, 2024.
Marquita Cullom,
Associate Director.
BILLING CODE 4160–90–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–R–38 and
CMS–10400]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
May 28, 2024.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
20:27 Mar 27, 2024
None.
• Hospital or other acute care settings.
• Non-English language text.
• Conference abstracts and other non-peer-reviewed
data.
When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: ll, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
[FR Doc. 2024–06595 Filed 3–27–24; 8:45 am]
VerDate Sep<11>2014
Exclusion criteria
Jkt 262001
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–R–38 Conditions for
Certification for Rural Health Clinics
and Conditions for Coverage for
Federally Qualified Health Centers in
42 CFR 491
CMS–10400 Establishment of
Qualified Health Plans and American
Health Benefit Exchanges
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Reinstatement of a previously
approved collection; Title of
Information Collection: Conditions for
Certification for Rural Health Clinics
and Conditions for Coverage for
Federally Qualified Health Centers in 42
CFR 491; Use: The Conditions for
Medicare Certification (CfCs) for Rural
Health Clinics (RHCs) are based on
criteria prescribed in law and designed
to ensure that each RHC has properly
trained staff to provide appropriate care
and to assure a safe physical
environment for patients. The
information collection requirements
described herein are needed to
implement the Medicare and Medicaid
CfCs for a total of 5,349 RHCs. These
requirements are similar in intent to
standards developed by industry
organizations such as the Joint
Commission on Accreditation of
Hospitals, and the National League of
Nursing/American Public Association,
and merely reflect accepted standards of
management and care to which rural
health clinics must adhere.
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 89, Number 61 (Thursday, March 28, 2024)]
[Notices]
[Pages 21521-21523]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06595]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Supplemental Evidence and Data Request on Fiber Intake and
Laxation Outcomes
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for supplemental evidence and data submission.
-----------------------------------------------------------------------
SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is
seeking scientific information submissions from the public. Scientific
information is being solicited to inform our review on Fiber Intake and
Laxation Outcomes, which is currently being conducted by the AHRQ's
Evidence-based Practice Centers (EPC) Program. Access to published and
unpublished pertinent scientific information will improve the quality
of this review.
DATES: Submission Deadline on or before April 29, 2024.
ADDRESSES:
Email submissions: [email protected].
Print submissions:
Mailing Address: Center for Evidence and Practice Improvement, Agency
for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600
Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857
Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice
Improvement, Agency for Healthcare Research and Quality, ATTN: EPC
SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD
20857
FOR FURTHER INFORMATION CONTACT: Kelly Carper, Telephone: 301-427-1656
or Email: [email protected].
SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and
Quality has commissioned the Evidence-based Practice Centers (EPC)
Program to complete a review of the evidence for Fiber Intake and
Laxation Outcomes. AHRQ is conducting this review pursuant to Section
902 of the Public Health Service Act, 42 U.S.C. 299a.
The EPC Program is dedicated to identifying as many studies as
possible that are relevant to the questions for each of its reviews. In
order to do so, we are supplementing the usual manual and electronic
database searches of the literature by requesting information from the
public (e.g., details of studies conducted). We are looking for studies
that report on Fiber Intake and Laxation Outcomes. The entire research
protocol is available online at: https://effectivehealthcare.ahrq.gov/products/fiber-intake/protocol.
This is to notify the public that the EPC Program would find the
following information on Fiber Intake and Laxation Outcomes helpful:
[ssquf] A list of completed studies that your organization has
sponsored for this topic. In the list, please indicate whether results
are available on ClinicalTrials.gov along with the ClinicalTrials.gov
trial number.
[ssquf] For completed studies that do not have results on
ClinicalTrials.gov, a summary, including the following elements, if
relevant: study number, study period, design, methodology, indication
and diagnosis, proper use instructions, inclusion and exclusion
criteria, primary and secondary outcomes, baseline characteristics,
number of patients screened/eligible/enrolled/lost to follow-up/
withdrawn/analyzed, effectiveness/efficacy, and safety results.
[ssquf] A list of ongoing studies that your organization has
sponsored for this topic. In the list, please provide the
ClinicalTrials.gov trial number or, if the trial is not registered, the
protocol for the study including, if relevant, a study number, the
study period, design, methodology, indication and diagnosis, proper use
instructions, inclusion and exclusion criteria, and primary and
secondary outcomes.
[ssquf] Description of whether the above studies constitute ALL
Phase II and above clinical trials sponsored by your organization for
this topic and an index outlining the relevant information in each
submitted file.
Your contribution is very beneficial to the Program. Materials
submitted must be publicly available or able to be made public.
Materials that are considered confidential; marketing materials; study
types not included in the review; or information on topics not included
in the review cannot be used by the EPC Program. This is a voluntary
request for information, and all costs for complying with this request
must be borne by the submitter.
The draft of this review will be posted on AHRQ's EPC Program
website and available for public comment for a period of 4 weeks. If
you would like to be notified when the draft is posted,
[[Page 21522]]
please sign up for the email list at: https://effectivehealthcare.ahrq.gov/email-updates.
The review will answer the following questions. This information is
provided as background. AHRQ is not requesting that the public provide
answers to these questions.
Key Question (KQ)
KQ 1: What is the association between fiber intake and laxation/gut
motility in apparently healthy individuals?
KQ 1a: How does the association vary among people in different life
stages?
PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, and
Setting)
Study Eligibility Criteria Based on Population, Intervention, Comparator, Outcome (PICO), and Other Elements
----------------------------------------------------------------------------------------------------------------
Element Inclusion criteria Exclusion criteria
----------------------------------------------------------------------------------------------------------------
Population............................... Individuals of any age, Those with
including pregnant or lactating women. diseases/health-related
General population, including conditions or taking
individuals with overweight/obese and medications that could
those at elevated cardiometabolic impact gut motility/
disease risk. laxation (e.g., irritable
[cir] Overweight/obese. bowel syndrome; chronic
[cir] Hyperglycemia and related constipation; lactose
conditions, including type 2 diabetes. intolerance; use of
[cir] Dyslipidemia. medications that stimulate
[cir] Hypertension/high blood pressure. laxation or cause
constipation).
Those with chronic
constipation (100% of
study population),
including functional
constipation.
Study eligibility
criteria includes
``abnormal laxation'' as
defined by either a
minimum or maximum number
of defecations per week
(or equivalent).
Those with other
gastrointestinal-related
conditions, symptoms,
diagnoses;
[cir] Including
diverticulosis.
Those with
diseases/health-related
conditions or taking
medications that could
alter the gut microbiota
composition/diversity
(e.g., antibiotics).
Those with cancer,
gastrointestinal disease,
undernutrition, or who
have had gut resection or
bariatric surgery.
Those with acute
illness or injury.
Pre-term babies
(gestational age <37
weeks), babies with low
birth weight (<2,500 g) or
small for gestational age
(per study criteria).
Enteral/tube fed.
Animal, in vitro,
or other non-human
studies.
Interventions............................ Fiber intake, including Diets (or other
different types and sources of fiber. interventions or
Fiber naturally occurring in exposures) where the fiber
food, enriched in food, dietary intake has not been
supplements, and diets that can be quantified or explicitly
defined on the basis of fiber content. specified.
[cir] Must specify quantity of fiber Combinations of
intake. fiber (from food or
dietary supplements) and
other entities with a
purported effect on
motility, digestion, or
microbiota (e.g., psyllium
+ probiotic).
Combinations of
fiber supplements and
other entities (e.g.,
minerals, vitamins).
Comparators.............................. Different levels (dosages) of Other entities
fiber. with a purported effect on
No added fiber or placebo. motility, digestion, or
Different types or sources of microbiota (e.g.,
fiber. probiotic).
Different formulations of Alternative food
fiber. group diets (e.g., red
meat, fish, high protein).
Interventions vs. Comparators............ Fiber (supplement) vs. no fiber Fiber + probiotic
(supplement). (etc.) vs. no intervention
Higher fiber (diet) vs. lower or placebo.
fiber (diet). Fiber + probiotic
Fiber vs. alternative fiber. (etc.) vs. same probiotic
Fiber vs. alternative fiber (etc.).
dose. Fiber vs.
Fiber vs. alternative fiber probiotic (etc.).
formulation. High-fiber diet
vs. red meat diet (etc.).
Outcomes................................. Laxation (i.e., gut motility). Other disease or
[cir] Fecal frequency (e.g., number of health outcomes.
defecations per week). Flatulence,
[cir] Gastrointestinal transit time. eructation, bloating, etc.
[ssquf] Bristol stool scale (stool
consistency).
[ssquf] Dye, marker studies.
[cir] Fecal output, weight/bulk (g/
day).
[cir] Ease of defecation (e.g.,
constipation).
Subgroups of interest.................... Specific life stages: None.
[cir] Infants.
[cir] Children and adolescents.
[cir] Adults (19-64).
[cir] Older adults (>=65).
[cir] Pregnant or postpartum.
[cir] Sex (male, female).
Design................................... Randomized controlled trials. Observational
[cir] Parallel or cross-over. studies.
N >=10/group. All other study
designs.
[[Page 21523]]
Timing................................... Minimum duration of None.
intervention: 2 weeks.
In cross-over studies, any
change in outcome measure must exclude
data from the first week after end of
any prior treatments. This may be
accomplished by a washout period of at
least 1 week.
Setting.................................. General population. Hospital or other
acute care settings.
Publication.............................. English language. Non-English
Published in peer-reviewed language text.
journals. Conference
abstracts and other non-
peer-reviewed data.
----------------------------------------------------------------------------------------------------------------
Dated: March 18, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024-06595 Filed 3-27-24; 8:45 am]
BILLING CODE 4160-90-P
